Phase 2
Completed N=41
Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
Raynaud Disease
Source: ClinicalTrials.gov NCT00251238 ↗
Enrolled (actual)
41
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Frequency of Vasospastic Attacks — 2.4; 2.0 attacks per day
Summary
The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Frequency of Vasospastic Attacks |
2.4; 2.0 | — |
| PRIMARY Duration of Vasospastic Attacks |
47.4; 50.9 | — |
| PRIMARY Change From Baseline in Severity of Vasospastic Attacks |
-1.3; -1.3 | — |
Eligibility Criteria
Inclusion Criteria
- Primary Raynaud´s phenomenon
- History of episodic digital or toe pallor
- Duration of Raynaud´s phenomenon at least 2 years
- Suffering form regular occuring attacks prior to enrolment
Exclusion Criteria
- Secondary Raynaud´s phenomenon
- Connective tissue disease
- Large vessel disease
- Cryoglobulinemia, cold agglutinins disease, thrombocytosis
- Concomitant pharmacological treatment with effects on the vasculature
- Pregnancy or lactation
- Severe internal or systemic disease
Data sourced from ClinicalTrials.gov (NCT00251238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.